Absci (ABSI) vs iSpecimen (ISPC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Absci is the larger company by market cap ($1.30 billion vs $2.6 million), about 491.1 times the size. iSpecimen converts more of its revenue into profit, with a net margin of -543.7% versus -4113.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABSI | ISPC |
|---|---|---|
| Share price | $7.51 | $0.4563 |
| Market cap | $1.30B | $2.64M |
| 1-day change | -7.97% | -13.58% |
| YTD return | +115.19% | — |
| 1-year return | +156.31% | — |
| 5-year return | -31.79% | — |
| EPS (TTM) | $-0.79 | $-52.98 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.80M | $1.93M |
| Revenue growth (YoY) | -38.24% | -79.24% |
| Net income (latest FY) | $-115.18M | $-10.49M |
| Gross margin | — | 11.18% |
| Operating margin | -4297.04% | -465.42% |
| Net margin | -4113.68% | -543.68% |
| 52-week high | $12.55 | $27.44 |
| 52-week low | $2.24 | $0.432 |
| Distance from 52-week high | -40.14% | -98.34% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +100.93% | — |
| Average volume | 4.08M | 598.66K |
| Shares outstanding | 172.75M | 5.79M |
| Employees | 140 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Absci is about 491.1 times larger than iSpecimen by market value ($1.30B vs $2.64M).
- iSpecimen is more profitable, keeping -543.7 cents of every revenue dollar as net income versus -4113.7 cents for Absci.
- Absci grew revenue faster in its latest fiscal year (-38.24% vs -79.24%).
About Absci
ABSI stock →Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 140 employees
About iSpecimen
ISPC stock →iSpecimen Inc. operates marketplace that provides biospecimens to life science researchers in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 7 employees
ABSI vs ISPC FAQ
Which is bigger, Absci or iSpecimen?
Absci (ABSI) is larger, with a market capitalization of $1.30B compared with $2.64M for iSpecimen (ISPC).
Are Absci and iSpecimen in the same industry?
Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.